Safety concerns Jurisdictional and approval rules vary across regulators, but a global scan reveals that only a scant few peptides in BPC-157s broader therapeutic class have achieved any clinically approved use
This formulation starts at approximately $80 per package
Klow Wolverine is the most comprehensive formulation in its class, combining four peptides: GHK-Cu (collagen, matrix), BPC-157 (angiogenesis, tendons), TB-500 (actin, anti-fibrosis), and KPV (NF-B inhibition, anti-inflammation)
The primary antibodies used were: anti-MOG (1:500, AB32760, Abcam), anti-MBP (1:300, MCA409S, BioRad), anti-APCCC1 (1:50, OP80, Sigma-Aldrich), anti-PDGFR (1:50, AF1062, R&D Systems), anti-OLIG2 (1:200, MABN50, Sigma-Aldrich), anti-Ki67 (1:500, 14569882, Thermo Fisher), anti-IBA1 (1:500, 234004, SYSY), anti-GFAP (1:500, 130300, Thermo Fisher), anti-GPX4 (1:200, ab25066, Abcam), anti-HMGB1 (1:200, ab18256, Abcam), anti-MAP2 (1:500, 822501, BioLegend), anti-SYN1 (1:500, D12G5, Cell Signaling Technology), anti-SHANK3 (1:500, 162304, Synaptic Systems), anti-EAAT1 (1:50, ab181036, Abcam), anti-ALDH1A1 (1:200, AF5869, R&D Systems), anti-C1Q (1:500, ab182451, Abcam), anti-C3 (1:500, 11862, Abcam), anti-RUNX1 (1:100, sc-365644, Santa Cruz Biotechnology), anti-MOBP (1:50, Thermo Fisher), and anti-PVALB (1:300, ab11427, Abcam), anti-ANKG (1:500, 386005, SySy)
